Table 2.
Within-group comparisons of clinical assessment scores.
| CT group (n = 9) | RBMT group (n = 10) | |||||
|---|---|---|---|---|---|---|
| Variable | Baseline | T 1 | T 2 | Baseline | T 1 | T 2 |
| FMA-UE | 22.56 ± 17.17 | 26.78 ± 18.95* | 30.11 ± 20.95† | 27.20 ± 17.03 | 31.90 ± 17.01* | 36.40 ± 16.87† |
| FMA-SE | 15.33 ± 10.61 | 17.00 ± 11.73 | 18.67 ± 13.33† | 19.90 ± 9.88 | 21.70 ± 9.38 | 23.00 ± 9.35† |
| FMA-WH | 7.22 ± 7.36 | 9.78 ± 7.74 | 11.44 ± 7.86† | 7.30 ± 8.11 | 10.10 ± 7.98* | 13.40 ± 7.73† |
| WMFT-FAS | 23.33 ± 17.80 | 26.33 ± 19.36 | 30.22 ± 20.02 | 24.20 ± 14.67 | 29.80 ± 15.64* | 33.60 ± 16.40† |
| WMFT-FT | 10.11 ± 10.06 | 12.78 ± 11.70 | 15.33 ± 13.27 | 9.50 ± 8.15 | 13.60 ± 9.89* | 16.20 ± 10.92† |
| WMFT-time(s) | 79.79 ± 38.80 | 70.56 ± 45.28* | 64.86 ± 44.47† | 71.07 ± 34.41 | 57.25 ± 39.9* | 53.05 ± 38.89† |
| ARAT | 12.67 ± 14.37 | 16.56 ± 17.33 | 18.44 ± 18.17 | 10.90 ± 10.33 | 15.50 ± 12.60 | 20.00 ± 16.51 |
T1 vs. baseline (*); T2 vs. baseline (†).
Significance levels are p < 0.017.